Failure to recover somatotropic axis function is associated with mortality from pediatric sepsis-induced multiple organ dysfunction syndrome

Pediatric Critical Care Medicine

Volumn 11, Issue 1, 2010, Pages 18-25

  Marquardt, David J ^a,b   Knatz, Nina L ^b   Wetterau, Lawrence A ^c   Wewers, Mark D ^a   Hall, Mark W ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c Department of Orthopaedic Surgery Central California Children's Hospital   (United States)

Author keywords

pediatric

Indexed keywords

ALBUMIN; CALCINEURIN INHIBITOR; DEXAMETHASONE; DOPAMINE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; METHYLPREDNISOLONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CHEMOLUMINESCENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; EX VIVO STUDY; FEMALE; GROWTH HORMONE SECRETING CELL; HUMAN; HYPOPHYSIS FUNCTION; HYPOTHALAMUS FUNCTION; INNATE IMMUNITY; INTENSIVE CARE UNIT; LYMPHOCYTE COUNT; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; SEPTIC SHOCK; SURVIVOR;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNE SYSTEM PHENOMENA; INFANT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MALE; MULTIPLE ORGAN FAILURE; PEDIATRICS; RETROSPECTIVE STUDIES; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75149128656     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181b06046     Document Type: Article

References (38)

1. Watson RS, Carcillo JA, Linde-Zwirble WT, et al: The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701
2. Leclerc F, Leteurtre S, Duhamel A, et al: Cumulative influence of organ dysfunctions and septic state on mortality of critically ill children. Am J Respir Crit Care Med 2005; 171:348-353
3. Van den Berghe G: Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 2002; 23:370-391
4. Van den Berghe G, Baxter RC, Weekers F, et al: The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002; 56:655-669
5. Rosenfeld RG, Cohen P: Disorders of growth hormone/insulin-like growth factor secretion and action. In: Pediatric Endocrinology. Sperling MA (Ed). Philadelphia, Saunders, 2002, pp 211-288
6. Cohen P: Insulin-like growth factor binding protein-3: Insulin-like growth factor independence comes of age. Endocrinology 2006; 147:2109-2111
7. Wetterau LA, Moore MG, Lee KW, et al: Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 1999; 68:161-181
8. Van den Berghe G: Endocrine evaluation of patients with critical illness. Endocrinol Metab Clin North Am 2003; 32:385-410
9. Haeffner A, Deas O, Mollereau B, et al: Growth hormone prevents human monocytic cells from Fas-mediated apoptosis by up-regulating Bcl-2 expression. Eur J Immunol 1999; 29:334-344
10. Uronen-Hansson H, Allen ML, Lichtarowicz-Krynska E, et al: Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood. Growth Horm IGF Res 2003; 13:282-286
11. Renier G, Clement I, Desfaits AC, et al: Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology 1996; 137:4611-4618
12. Felmet KA, Hall MW, Clark RS, et al: Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005; 174:3765-3772
13. Hall MW, Gavrilin MA, Knatz NL, et al: Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ dysfunction syndrome. Pediatr Res 2007; 62:597-603
14. Doughty LA, Kaplan SS, Carcillo JA: Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med 1996; 24:1137-1143
15. Goldstein B, Giroir B, Randolph A, et al: International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8
16. Pollack MM, Patel KM, Ruttimann UE: PRISM III: An updated pediatric risk of mortality score. Crit Care Med 1996; 24:743-752
17. Leteurtre S, Martinot A, Duhamel A, et al: Validation of the paediatric logistic organ dysfunction (PELOD) score: Prospective, observational, multicentre study. Lancet 2003; 362:192-197
18. Van den Berghe G, de Zegher F, Bowers CY, et al: Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Clin Endocrinol (Oxf) 1996; 45:341-351
19. Van den Berghe G, de Zegher F, Baxter RC, et al: Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998; 83:309-319
20. Balcells J, Moreno A, Audi L, et al: Growth hormone/insulin-like growth factors axis in children undergoing cardiac surgery. Crit Care Med 2001; 29:1234-1238
21. de Groof F, Joosten KF, Janssen JA, et al: Acute stress response in children with meningococcal sepsis: Important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. J Clin Endocrinol Metab 2002; 87:3118-3124
22. Onenli-Mungan N, Yildizdas D, Yapicioglu H, et al: Growth hormone and insulin-like growth factor 1 levels and their relation to survival in children with bacterial sepsis and septic shock. J Paediatr Child Health 2004; 40:221-226
23. Gardelis JG, Hatzis TD, Stamogiannou LN, et al: Activity of the growth hormone/insulin-like growth factor-I axis in critically ill children. J Pediatr Endocrinol Metab 2005; 18:363-372
24. Mesotten D, Wouters PJ, Peeters RP, et al: Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. J Clin Endocrinol Metab 2004; 89:3105-3113
25. Langouche L, Vanhorebeek I, Van den Berghe G: Therapy insight: The effect of tight glycemic control in acute illness. Nat Clin Pract Endocrinol Metab 2007; 3:270-278
26. Broglio F, Prodam F, Riganti F, et al: Ghrelin: From somatotrope secretion to new perspectives in the regulation of peripheral metabolic functions. Front Horm Res 2006; 35:102-114
27. Prince AC, Brooks SJ, Stahl D, et al: Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders. Am J Clin Nutr 2009; 89:755-765
28. Frost RA, Lang CH: Alteration of somatotropic function by proinflammatory cytokines. J Anim Sci 2004; 82(E-Suppl):E100-E109
29. Liu ML, Xu G, Xue SR, et al: Plasma levels of Th1/Th2 type cytokine are associated with change of prolactin and GH/IGF-I in hemodialysis patients. Int J Artif Organs 2008; 31:303-308
30. Dantzer R: Cytokine-induced sickness behavior: Mechanisms and implications. Ann N Y Acad Sci 2001; 933:222-234
31. Takala J, Ruokonen E, Webster NR, et al: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792
32. Jeschke MG, Finnerty CC, Kulp GA, et al: Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. Pediatr Crit Care Med 2008; 9:209-216
33. Duska F, Fric M, Waldauf P, et al: Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation. Crit Care Med 2008; 36:1707-1713
34. Van den Berghe G, Wouters P, Weekers F, et al: Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84:1311-1323
35. Chang L, Zhao J, Yang J, et al: Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol 2003; 473:171-176
36. Li WG, Gavrila D, Liu X, et al: Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004; 109:2221-2226
37. Waseem T, Duxbury M, Ito H, et al: Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 2008; 143:334-342
38. Martin PL: To stop or not to stop: How much support should be provided to mechanically ventilated pediatric bone marrow and stem cell transplant patients? Respir Care Clin N Am 2006; 12:403-419